Global Precision Medicine Software Market to Reach $2.6 Billion by 2027
Abstract: - Global Precision Medicine Software Market to Reach $2. 6 Billion by 2027. - Amid the COVID-19 crisis, the global market for Precision Medicine Software estimated at US$1.
New York, July 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Precision Medicine Software Industry" - https://www.reportlinker.com/p06032637/?utm_source=GNW
3 Billion in the year 2020, is projected to reach a revised size of US$2.6 Billion by 2027, growing at aCAGR of 10.1% over the period 2020-2027. On-Premise, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cloud segment is readjusted to a revised 11.1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $352.1 Million, While China is Forecast to Grow at 13.4% CAGR
- The Precision Medicine Software market in the U.S. is estimated at US$352.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$537.8 Million by the year 2027 trailing a CAGR of 13.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7% and 8.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.
- Select Competitors (Total 34 Featured) -
2bprecise, LLC
Fabric Genomics, Inc.
Foundation Medicine, Inc.
Gene42, Inc.
Human Longevity, Inc.
Lifeomic Health, LLC
N-Of-One, Inc. (A Subsidiary of Qiagen N.V.)
Pieriandx, Inc.
Sophia Genetics Sa
Sunquest Information Systems, Inc.
Syapse, Inc.
Translational Software Inc.
Read the full report: https://www.reportlinker.com/p06032637/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Precision Medicine
Software by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Precision Medicine Software
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Precision Medicine
Software by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2020 & 2027
Table 4: World Current & Future Analysis for On-Premise by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 5: World Historic Review for On-Premise by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for On-Premise by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Cloud by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 8: World Historic Review for Cloud by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Cloud by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 11: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Healthcare
Providers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Healthcare Providers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Healthcare Providers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Research Centers &
Academic Institutes by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Research Centers & Academic
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Research Centers &
Academic Institutes by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027
Table 19: World Current & Future Analysis for Pharma & Biotech
Companies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Pharma & Biotech Companies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Pharma & Biotech
Companies by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
Table 22: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 23: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 24: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 25: World Current & Future Analysis for Pharmacogenomics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 26: World Historic Review for Pharmacogenomics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 27: World 15-Year Perspective for Pharmacogenomics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 28: World Current & Future Analysis for Rare Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 29: World Historic Review for Rare Diseases by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 30: World 15-Year Perspective for Rare Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 31: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 32: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 33: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
Table 34: USA Current & Future Analysis for Precision Medicine
Software by Deployment - On-Premise and Cloud - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR
Table 35: USA Historic Review for Precision Medicine Software
by Deployment - On-Premise and Cloud Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 36: USA 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 37: USA Current & Future Analysis for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 38: USA Historic Review for Precision Medicine Software
by End-Use - Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 39: USA 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 40: USA Current & Future Analysis for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 41: USA Historic Review for Precision Medicine Software
by Application - Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 42: USA 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
CANADA
Table 43: Canada Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 44: Canada Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 45: Canada 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 46: Canada Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 47: Canada Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 48: Canada 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 49: Canada Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 50: Canada Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 51: Canada 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
JAPAN
Table 52: Japan Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 53: Japan Historic Review for Precision Medicine Software
by Deployment - On-Premise and Cloud Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 54: Japan 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 55: Japan Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 56: Japan Historic Review for Precision Medicine Software
by End-Use - Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 57: Japan 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 58: Japan Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 59: Japan Historic Review for Precision Medicine Software
by Application - Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 60: Japan 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
CHINA
Table 61: China Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 62: China Historic Review for Precision Medicine Software
by Deployment - On-Premise and Cloud Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 63: China 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 64: China Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 65: China Historic Review for Precision Medicine Software
by End-Use - Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 66: China 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 67: China Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 68: China Historic Review for Precision Medicine Software
by Application - Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 69: China 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
EUROPE
Table 70: Europe Current & Future Analysis for Precision
Medicine Software by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 71: Europe Historic Review for Precision Medicine
Software by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 72: Europe 15-Year Perspective for Precision Medicine
Software by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2020 & 2027
Table 73: Europe Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 74: Europe Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 75: Europe 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 76: Europe Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 77: Europe Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 78: Europe 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 79: Europe Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 80: Europe Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 81: Europe 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
FRANCE
Table 82: France Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 83: France Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 84: France 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 85: France Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 86: France Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 87: France 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 88: France Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 89: France Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 90: France 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
GERMANY
Table 91: Germany Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 92: Germany Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 93: Germany 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 94: Germany Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 95: Germany Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 96: Germany 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 97: Germany Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 98: Germany Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 99: Germany 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
ITALY
Table 100: Italy Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 101: Italy Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 102: Italy 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 103: Italy Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 104: Italy Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 105: Italy 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 106: Italy Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 107: Italy Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 108: Italy 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 109: UK Current & Future Analysis for Precision Medicine
Software by Deployment - On-Premise and Cloud - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR
Table 110: UK Historic Review for Precision Medicine Software
by Deployment - On-Premise and Cloud Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 111: UK 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 112: UK Current & Future Analysis for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 113: UK Historic Review for Precision Medicine Software
by End-Use - Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR
Table 114: UK 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 115: UK Current & Future Analysis for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 116: UK Historic Review for Precision Medicine Software
by Application - Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 117: UK 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
SPAIN
Table 118: Spain Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 119: Spain Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 120: Spain 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027
Table 121: Spain Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 122: Spain Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 123: Spain 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027
Table 124: Spain Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 125: Spain Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 126: Spain 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027
RUSSIA
Table 127: Russia Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032637/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001